Repatha and Alphagan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Repatha (evolocumab) and Alphagan (brimonidine tartrate). Common drug interactions include arthritis among females and acute myocardial infarction among males.

The phase IV clinical study analyzes what interactions people have when they take Repatha and Alphagan. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Repatha?

Repatha has active ingredients of evolocumab. It is often used in high blood cholesterol. eHealthMe is studying from 156,256 Repatha users. Check the latest studies of Repatha.

What is Alphagan?

Alphagan has active ingredients of brimonidine tartrate. It is often used in glaucoma. eHealthMe is studying from 9,981 Alphagan users. Check the latest studies of Alphagan.

On Jul, 12, 2026

17 people who take Repatha and Alphagan together, and have interactions are studied.

What are the common drug interactions of Repatha and Alphagan, by gender? *:

female:

Arthritis (form of joint disorder that involves inflammation of one or more joints)
Injection site haemorrhage (bleeding from injection site)
Injection site pain
Contusion (a type of hematoma of tissue in which capillaries)
Myalgia (muscle pain)
Injection site bruising
Dry eye (lack of adequate tears)
Fatigue (feeling of tiredness)
Glycosylated haemoglobin increased
Histoplasmosis (infection caused by breathing in spores of a fungus)

male:

Acute myocardial infarction (acute heart attack)
Amaurosis fugax (painless transient monocular visual loss)
Drug ineffective
Eye disorder
Fatigue (feeling of tiredness)
Glomerular filtration rate decreased
Hyperkalaemia (damage to or disease of the kidney)
Hypotension (abnormally low blood pressure)
Hypovolaemia (a decreased volume of circulating blood in the body)
Loss of consciousness

What are the common drug interactions of Repatha and Alphagan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Dry eye (lack of adequate tears)
Fatigue (feeling of tiredness)
Glycosylated haemoglobin increased
Histoplasmosis (infection caused by breathing in spores of a fungus)
Malaise (a feeling of general discomfort or uneasiness)
Myalgia (muscle pain)
Rhinorrhoea (watery mucus discharge from the nose)
Visual impairment

60+:

Arthritis (form of joint disorder that involves inflammation of one or more joints)
Injection site haemorrhage (bleeding from injection site)
Blood creatinine increased
Blood glucose increased
Blood urea increased
Carotid artery stenosis (narrowing of carotid artery)
Drug ineffective
Eye disorder
Fatigue (feeling of tiredness)
Glomerular filtration rate decreased

What are the existing conditions these people have? *

Atherosclerosis (disorder of the arteries): 4 people, 23.53%
Arteriosclerosis Coronary Artery (thickening and hardening of arteries- coronary artery): 4 people, 23.53%
Dyslipidaemia (abnormal amount of lipids): 3 people, 17.65%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 3 people, 17.65%
Pain: 2 people, 11.76%
Heart Disease: 2 people, 11.76%
Heart Attack: 2 people, 11.76%
Depression: 2 people, 11.76%
Carotid Artery Stenosis (narrowing of carotid artery): 2 people, 11.76%
Neurotrophic Keratopathy (decreased corneal sensitivity and poor corneal healing): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Repatha and Alphagan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously